Evidence map›Paper›PMID 39844639›Full record

ArticlePsychiatric services (Washington, D.C.)2025

Changes in Recovery Assessment Scale Scores During a Treatment Episode Among Patients in a Large Behavioral Health Care System.

Loreen Straub, Shelbi A Cox, Lauren V Moran, Matthew Ruble, Rajendra Aldis, Jason B Gibbons, Jun Liu, John Peloquin, Rachel Wood, Alyson Albano and 3 more

Abstract read
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Loreen StraubDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Shelbi A CoxDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Lauren V MoranDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Matthew RubleDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Rajendra AldisDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Jason B GibbonsDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Jun LiuDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
John PeloquinDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Rachel WoodDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Alyson AlbanoDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Josephine S AuDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Jennifer R HenrettyDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).
Philip S WangDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston (Straub, Moran, Aldis, Liu, Au, Wang); Discovery Behavioral Health, Discovery Medical Services, Irvine, California (Cox, Ruble, Peloquin, Wood, Albano, Henretty); Department of Psychiatry, Mclean Hospital, Harvard Medical School, Boston (Moran, Au); Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, Boston (Aldis); Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (Gibbons).

Funding

RESEARCH TRAINING IN PEDIATRIC EMERGENCY MEDICINET32HD040128 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI Kenneth D. Mandl · 2001 to 2026
$5.0M
Training Program in Comparative Effectiveness Research for Suicide PreventionT32MH125815 · NIMH · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI MIGUEL HERNAN, MATTHEW K NOCK · 2022 to 2026
$1.2M
NICHD NIH HHS T32 HD040128NIMH NIH HHS T32 MH125815
6 · The paper itself

Abstract

objectiveThe authors utilized patient-reported outcomes from a large U.S. behavioral health care system to evaluate the strength of improvements in patients' self-perceived recovery during mental health treatment.

methodsThis was a cohort study conducted with electronic health records from 2021-2022 Discovery Behavioral Health patients. Patients were grouped according to their 41-item Recovery Assessment Scale (RAS) scores at admission. Linear regression models accounting for patient characteristics were used to estimate RAS score changes from admission to discharge and RAS score at discharge.

resultsOf 9,441 patients, those belonging to groups with lower RAS scores at admission showed substantial score improvements, although their scores at discharge were still much lower compared with those of patients with higher admission scores. Results were consistent across secondary analyses.

conclusionsSubstantial improvements in recovery were evident during treatment, especially for patients with lower RAS scores at admission. The findings underline the importance of research into enhanced personalized treatment approaches to optimize recovery.

Indexed as

Mental DisordersMental Health ServicesPatient Reported Outcome MeasuresAdultCohort StudiesElectronic Health RecordsFemaleHumansMaleMiddle AgedPatient DischargeUnited StatesClinical outcome measurementMental illnessPatient reported outcomesRecovery

Identifiers

PMID39844639
PMCPMC12045741

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.